Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ABBV

ABBV - AbbVie Inc Stock Price, Fair Value and News

$218.68-5.25 (-2.34%)
Market Closed

28/100

ABBV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

28/100

ABBV

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$175.41

Target 3M

$197.77

Target 6M

$186.37

ABBV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABBV Price Action

Last 7 days

1.2%

Last 30 days

-5.3%

Last 90 days

-4.2%

Trailing 12 Months

25.1%

ABBV RSI Chart

ABBV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABBV Valuation

Market Cap

386.5B

Price/Earnings (Trailing)

161.85

Price/Sales (Trailing)

6.48

EV/EBITDA

183.02

Price/Free Cashflow

19.63

ABBV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$175.41

Target 3M

$197.77

Target 6M

$186.37

ABBV Fundamentals

ABBV Revenue

Revenue (TTM)

59.6B

Rev. Growth (Yr)

9.1%

Rev. Growth (Qtr)

2.29%

ABBV Earnings

Earnings (TTM)

2.4B

Earnings Growth (Yr)

-88.08%

Earnings Growth (Qtr)

-80.17%

ABBV Profitability

EBT Margin

2.78%

Return on Equity

-91.88%

Return on Assets

1.78%

Free Cashflow Yield

5.09%

ABBV Investor Care

Dividend Yield

2.93%

Dividend/Share (TTM)

6.56

Shares Dilution (1Y)

0.01%

Diluted EPS (TTM)

1.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202557.4B58.3B59.6B0
202454.4B55.0B55.5B56.3B
202356.7B56.0B55.1B54.3B
202256.7B57.3B57.8B58.1B
202150.2B53.7B55.2B56.2B
202034.1B36.2B40.6B45.8B
201932.6B32.6B32.9B33.3B
201829.6B30.9B32.2B32.8B
201726.2B26.7B27.3B28.2B
201623.8B24.8B25.2B25.6B
201520.4B21.0B21.9B22.9B
201419.0B19.3B19.6B20.0B
201318.5B18.7B18.9B18.8B
201217.7B17.9B18.1B18.4B
201100017.4B
201000015.6B
Get all data in R, Python etc through our Historical Stock Data APIs

About AbbVie Inc

ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
 CEO
 WEBSITEabbvie.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers General
 EMPLOYEES50000

AbbVie Inc Frequently Asked Questions

ABBV is the stock ticker symbol of AbbVie Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of AbbVie Inc is 386.49 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ABBV's fair value in chart for subscribers.

The fair value guage provides a quick view whether ABBV is over valued or under valued. Whether AbbVie Inc is cheap or expensive depends on the assumptions which impact AbbVie Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABBV.

As of Wed Jan 28 2026, ABBV's PE ratio (Price to Earnings) is 161.85 and Price to Sales (PS) ratio is 6.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABBV PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, AbbVie Inc has provided 0.148 (multiply by 100 for percentage) rate of return.